Table 1 The patient characteristics and treatment methods
| Â | Prostate MRI | p | |
|---|---|---|---|
Yes (n = 189) | No (n = 221) | ||
No. of patients (%) | No. of patients (%) | ||
Age, years | Â | Â | 0.50 |
 Median (range) | 73 (57–85) | 74 (47–84) |  |
T stagea | Â | Â | 0.82 |
 T1–2 | 144 (76) | 171 (77) |  |
 T3–4 | 45 (24) | 50 (23) |  |
iPSA (ng/mL) | Â | Â | 0.91 |
 <10 | 60 (32) | 74 (33) |  |
 10–20 | 57 (30) | 68 (31) |  |
 >20 | 71 (38) | 79 (36) |  |
 Not specified | 1 (0) | 0 (0) |  |
Gleason score | Â | Â | 0.68 |
 2–6 | 77 (41) | 83 (38) |  |
 7 | 65 (34) | 82 (37) |  |
 8–10 | 40 (21) | 53 (24) |  |
 Not specified | 7 (4) | 3 (1) |  |
Risk groups | Â | Â | 0.48 |
 Low | 24 | 36 |  |
 Intermediate | 60 (32) | 72 |  |
 High | 85 | 97 |  |
 Very high | 16 | 15 |  |
 Not specified | 4 | 1 |  |
Date of treatment | Â | Â | <0.001 |
 1998–2005 | 117 (62) | 82 (37) |  |
 2006–2009 | 72 (38) | 139 (63) |  |
ADT | Â | Â | <0.001 |
 <6 months | 17 (9) | 46 (21) |  |
 ≥6 months | 171 (90) | 167 (76) |  |
 None | 1 (1) | 8 (3) |  |
Radiation dose | Â | Â | <0.0001 |
 66 Gy | 87 (46) | 58 (26) |  |
 70 Gy | 100 (53) | 162 (74) |  |
 Other | 2 (1) | 1 (0) |  |
Hyperthermia | Â | Â | 0.53 |
 Yes | 62 (33) | 79 (36) |  |
 No | 127 (67) | 142 (64) |  |